MediciNova (TSE:4875) Interest Expense: 円0.00 Mil (TTM As of Mar. 2026)

What is MediciNova Interest Expense?

MediciNova TSE:4875 +2.26% 28 Interest Expense is 円0.00 Mil as of Mar. 2026. GuruFocus rates TSE:4875 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. MediciNova's interest expense for the three months ended in Mar. 2026 was 円 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. MediciNova's Operating Income for the three months ended in Mar. 2026 was 円 -450.02 Mil. MediciNova's Interest Expense for the three months ended in Mar. 2026 was 円 0.00 Mil. MediciNova has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

MediciNova (TSE:4875) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MediciNova's Interest Expense for the three months ended in Mar. 2026 was 円0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was 円-450.02 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was 円0.00 Mil.

MediciNova's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

MediciNova had no long-term debt ⁽¹⁾.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. MediciNova Inc has enough cash to cover all of its debt. Its financial situation is stable.

MediciNova Interest Expense Historical Data

* Premium members only.

The historical data trend for MediciNova's Interest Expense can be seen below:

MediciNova Interest Expense Chart

MediciNova Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

0.00

MediciNova Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

28GF Score

MediciNova Inc TSE:4875

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

MediciNova Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of 円0.00 Mil mean?

MediciNova (TSE:4875) has a Interest Expense of 円0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on MediciNova and its competitors.

Is MediciNova's Interest Expense too high?

MediciNova's current Interest Expense is 円0.00 Mil. Overall, MediciNova has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does MediciNova's Interest Expense compare to TCRX and PMVP?

MediciNova's Interest Expense of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on MediciNova and its competitors. MediciNova's current Interest Expense is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is MediciNova stock overvalued right now?

MediciNova (TSE:4875) has a current Interest Expense of 円0.00 Mil. The current Interest Expense is 円0.00 Mil. MediciNova's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For MediciNova (TSE:4875), the current Interest Expense is 円0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MediciNova Business Description

Industry Healthcare Biotechnology

Comparable Companies TCRX PMVP BSEM CING IMA XLO FLNA MCRB BOLD PLRX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges MNOV:USA

Address 4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037

Website https://www.medicinova.com

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

28GF Score

Get the complete analysis for TSE:4875

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円226.00

Price

View TSE:4875 Analysis

See Interest Expense data for all stocks →